LIXTE Advances Cancer Therapy with World’s Only Clinical-Stage PP2A Inhibitor
LIXTE Biotechnology’s LB-100 is the world’s only clinical-stage PP2A inhibitor, shown safe in Phase 1 trials and supported by over 25 preclinical studies. The small-molecule compound enhances immunotherapy and chemotherapy sensitivity while disrupting cancer cell repair mechanisms.
1. Lead Compound Overview
LIXTE’s lead asset, LB-100, is the first and only clinical-stage inhibitor of protein phosphatase 2A (PP2A). By targeting PP2A, LB-100 increases cancer cell vulnerability to immunotherapy and chemotherapy while interfering with the cells’ internal repair systems.
2. Clinical and Preclinical Data
Phase 1 trials of LB-100 demonstrated a favorable safety profile, with no dose-limiting toxicities reported. More than 25 published preclinical and translational studies support the compound’s mechanism and potential synergistic effects with existing cancer treatments.
3. Strategic Outlook
LIXTE plans to advance LB-100 into Phase 2 trials to evaluate efficacy endpoints and optimal combination regimens. The company is exploring strategic partnerships and additional indications to position LB-100 as a new treatment paradigm in oncology.